Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)

Area of Science:

• Oncology
• Molecular Genetics
• Pharmacology

Background:

• Chemotherapy alone reached a therapeutic plateau for advanced non-small cell lung cancer (NSCLC).
• Molecular genetics advances revealed distinct NSCLC subsets, enabling targeted therapies.
• Tumor genotyping for EGFR mutations and ALK rearrangements now guides first-line treatment decisions.

Purpose of the Study:

• To review the current status of clinically relevant driver mutations in lung cancer.
• To discuss emerging molecular subsets in lung adenocarcinoma and squamous cell carcinoma.
• To explore the role of targeted therapy and acquired resistance mechanisms.

Main Methods:

• Literature review of recent advancements in NSCLC molecular profiling.
• Analysis of targeted therapy efficacy and resistance patterns.
• Synthesis of data on driver mutations and novel molecular subsets.

Main Results:

• Molecularly targeted therapies have significantly improved clinical outcomes in NSCLC.
• Genotyping for specific mutations (e.g., EGFR, ALK) is now standard for treatment selection.
• Understanding acquired resistance is crucial for optimizing long-term patient management.

Conclusions:

• Targeted therapy represents a paradigm shift in advanced NSCLC treatment.
• Continued research into novel molecular targets and resistance mechanisms is essential.
• Personalized medicine approaches are transforming lung cancer care.